TipRanks
Advertisement
Advertisement

LRMR Stock Latest News

Larimar Therapeutics Appoints New President and COO
Company AnnouncementsLarimar Therapeutics Appoints New President and COO
24d ago
8K
LRMR
Larimar Therapeutics appoints John Harlow as COO
PremiumThe Fly
Larimar Therapeutics appoints John Harlow as COO
24d ago
LRMR
Larimar Therapeutics assumed with an Outperform at Leerink
PremiumThe Fly
Larimar Therapeutics assumed with an Outperform at Leerink
1M ago
LRMR
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play
PremiumCompany Announcements
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play
2M ago
LRMR
Larimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor Spotlight
PremiumCompany Announcements
Larimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor Spotlight
2M ago
LRMR
Larimar Therapeutics price target lowered to $11 from $12 at Wedbush
PremiumThe FlyLarimar Therapeutics price target lowered to $11 from $12 at Wedbush
3M ago
LRMR
Larimar Therapeutics: Buy Rating Reaffirmed as FDA-Backed Nomlabofusp Progress Supports Unchanged $25 Price Target
Premium
Ratings
Larimar Therapeutics: Buy Rating Reaffirmed as FDA-Backed Nomlabofusp Progress Supports Unchanged $25 Price Target
3M ago
LRMR
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch
Premium
Ratings
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch
3M ago
LRMR
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
PremiumCompany Announcements
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
3M ago
LRMR
Larimar Therapeutics reports Q2 EPS (30c), consensus (38c)
PremiumThe Fly
Larimar Therapeutics reports Q2 EPS (30c), consensus (38c)
3M ago
LRMR
Larimar reports Q2 results and nomlabofusp progress
PremiumCompany Announcements
Larimar reports Q2 results and nomlabofusp progress
3M ago
8K
LRMR
Larimar Therapeutics, Inc. (LRMR) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Larimar Therapeutics, Inc. (LRMR) Q2 Earnings Cheat Sheet
3M ago
LRMR
Buy Rating Reaffirmed on Growing Nomlabofusp Confidence; $25 Price Target Maintained
PremiumRatingsBuy Rating Reaffirmed on Growing Nomlabofusp Confidence; $25 Price Target Maintained
3M ago
LRMR
Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up
Premium
Weekend Updates
Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up
3M ago
CYTK
GLBE
Closing Bell Movers: Levi Strauss down 6% on earnings
Premium
The Fly
Closing Bell Movers: Levi Strauss down 6% on earnings
4M ago
AP
AZZ
Larimar Therapeutics director buys $167K in common stock
PremiumThe Fly
Larimar Therapeutics director buys $167K in common stock
4M ago
LRMR
Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts
PremiumWeekend Updates
Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts
4M ago
CVX
ADBE
Citizens biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens biotech analysts hold an analyst/industry conference call
4M ago
BIIB
DSGN
Larimar Therapeutics assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Larimar Therapeutics assumed with a Buy at H.C. Wainwright
4M ago
LRMR
Larimar Therapeutics price target lowered to $5 from $7 at Baird
PremiumThe FlyLarimar Therapeutics price target lowered to $5 from $7 at Baird
4M ago
LRMR
Larimar Therapeutics selloff a buying opportunity, says Citi
Premium
The Fly
Larimar Therapeutics selloff a buying opportunity, says Citi
4M ago
LRMR
Larimar Therapeutics: Buy Rating on Nomlabofusp’s Robust FA Efficacy and De-Risked Regulatory Pathway
Premium
Ratings
Larimar Therapeutics: Buy Rating on Nomlabofusp’s Robust FA Efficacy and De-Risked Regulatory Pathway
4M ago
LRMR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >